Search clinical trials for: PMX-30063-investigational drug

Total 987 results

PolyMedix, Inc.

Completed

Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus

Acute Bacterial Skin and Skin-structure Infection(ABSSSI) Due to Staphylococcus Aureus (MSSA) | (Susceptible or Methicillin Resistant)

Canada, Russian Federation, Ukraine
Spectral Diagnostics (US) Inc.

No longer available

Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19

Septic Shock | Endotoxemia | COVID | Corona Virus Infection | Sepsis, Severe

United States
Seqirus

Completed

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults

Influenza

Australia, New Zealand, Philippines, South Africa
Spectral Diagnostics (US) Inc.

Completed

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock (EUPHRATES)

Septic Shock | Endotoxemia

United States, Canada
Cosmo Technologies Ltd

Completed

The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy

Colorectal Cancer

United States, Belgium, Canada, Germany, Italy, Lithuania, Netherlands, United Kingdom
Merck Sharp & Dohme LLC

Terminated

The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease

Alzheimer Disease

United States
GlaxoSmithKline

Completed

An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.

Epilepsy

United States
GlaxoSmithKline

Completed

Single Dose Escalation First Time in Human PK Study

Infections, Bacterial

Australia
Pfizer

Completed

Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

United States
Pfizer

Completed

Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma

Multiple Myeloma

United States
Avelas Biosciences, Inc.
Clinipace Worldwide; RRD International, Inc.

Completed

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Stage I Breast Cancer | Stage II Breast Cancer | Carcinoma, Ductal, Breast | Breast Cancer Female | Stage III Breast Cancer | Carcinoma Breast | Primary Invasive Malignant Neoplasm of Female Breast

United States
Cancer Intelligence Care Systems, Inc.
Stella Pharma Corporation

Completed

Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma

Angiosarcoma | Malignant Melanoma

Japan
Spectral Diagnostics (US) Inc.

Temporarily not available

Open-label Evaluation of Polymyxin B Hemoperfusion for Septic Shock (EUPHORIA)

Septic Shock | Endotoxemia
National Taiwan University Hospital

Completed

Endotoxin Adsorber Hemoperfusion and Microcirculation

Sepsis

Taiwan
PolyMedix, Inc.

Terminated

Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Percutaneous Coronary Intervention | Coronary Artery Disease (CAD) | Angioplasty

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults

Infections, Staphylococcal

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

Tetanus Immunisation (Healthy Volunteers) | Diphtheria Immunisation (Healthy Volunteers) | Pertussis Immunisation (Healthy Volunteers)

Canada
GlaxoSmithKline

Active, not recruiting

Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.

Sexually Transmitted Diseases

United States, Germany, Philippines, France, Spain, South Africa, United Kingdom, Brazil
Introgen Therapeutics
M.D. Anderson Cancer Center

Unknown

Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

Neoplasm Metastasis | Malignant Melanoma

United States
Changhai Hospital

Recruiting

Personalized Precision Diagnosis and Treatment of Pancreatic Cancer (PPDTPC)

Pancreatic Cancer

China
GlaxoSmithKline

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

Influenza

United States
Boston Scientific Corporation

Completed

The EVOLVE China Clinical Trial (EVOLVE-CHINA)

Coronary Artery Disease

China
VIST - Faculty of Applied Sciences
Slovenian Research Agency; Tosla d.o.o.

Completed

The Effect of 12-week Dietary Intake of Food Supplements Containing Collagen on Dermis Density and Other Skin Parameters (TO-COSKIN)

Wrinkles | Skin Elasticity | Skin Hydration | Trans Epidermal Water Loss (TEWL) | Dermis Density | Dermis Thickness | Skin Texture

Slovenia
Novartis

Completed

Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery

Epilepsy | Seizures

Germany
Spectral Diagnostics (US) Inc.

Recruiting

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study (TIGRIS)

Septic Shock | Endotoxemia

United States
GlaxoSmithKline

Completed

Prevention of Seasonal Affective Disorder

Seasonal Affective Disorder (SAD)

United States, Canada
Amgen

Completed

Single Ascending Dose Study of AMG 570 in Healthy Subjects

Systemic Lupus Erythematosus

United States
University Children's Hospital Basel
Permamed AG, Switzerland; Galvita AG, Switzerland

Completed

Bioequivalence of a Single-dose of 12 mg IVERMECTIN as Orally Disintegrating Mini Tablets Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets in Healthy Adults Under Fasting Conditions (CHILD-IVITAB)

Bioequivalence

Switzerland
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

Influenza

United States, Canada
Mead Johnson Nutrition

Completed

Acceptance Of A Partially-Hydrolyzed Infant Formula

Stool

United States
GlaxoSmithKline

Completed

Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.

Metastatic Breast Cancer | Neoplasms, Breast

United States
Meditor SAS

Completed

Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock (ABDO-MIX)

Septic Shock | Peritonitis

France
Duke University
National Institute on Drug Abuse (NIDA)

Recruiting

Low Nicotine Cigarettes, Smoking, and Chronic Pain (VLNCPain)

Chronic Pain | Smoking, Cigarette

United States
Mead Johnson Nutrition
Baylor College of Medicine

Completed

Assessing Early Behavioral Indicators of Formula Tolerance

Tolerance

United States
International AIDS Vaccine Initiative
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines

HIV Infections

Kenya, Zambia, Uganda
Princess Maxima Center for Pediatric Oncology
European Commission

Recruiting

CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

Acute Myeloid Leukemia in Children

Netherlands
GlaxoSmithKline

Recruiting

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Respiratory Syncytial Virus Infections

United States, Canada, Japan, Germany, Australia, South Africa
GlaxoSmithKline

Active, not recruiting

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above (RSV OA=ADJ-023)

Respiratory Syncytial Virus Infections

Spain, Japan, Italy, United States, Australia, Canada, Korea, Republic of, Germany
GlaxoSmithKline

Active, not recruiting

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

United States, Finland, Germany, Japan, Taiwan
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children

Influenza

Germany
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Belgium
NovaDigm Therapeutics, Inc.
United States Department of Defense; Cetero Research, San Antonio

Completed

Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida

Candidiasis | Staphylococcal Infections

United States
Meissa Vaccines, Inc.

Completed

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children

Respiratory Syncytial Virus Infections

United States
Alcon Research

Completed

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41

Ocular Hypertension | Open-Angle Glaucoma

United States
Alcon Research

Completed

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70

Ocular Hypertension | Open-Angle Glaucoma

United States
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Germany
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Jiangsu Province Center for...

Active, not recruiting

A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age

Varicella

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine

Prevention of Influenza

China
Alcon Research

Completed

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69

Ocular Hypertension | Open-Angle Glaucoma

United States

3

Subscribe